Modified Ham test for atypical hemolytic uremic syndrome
Open Access
- 4 June 2015
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 125 (23) , 3637-3646
Abstract
Key Points: GPI-anchor–deficient cell lines are more vulnerable to complement C5b-9 deposition and cell killing from aHUS serum. PIGA-null reagent cell lines can be used to rapidly and reliably distinguish aHUS from other thrombotic microangiopathies.Keywords
This publication has 47 references indexed in Scilit:
- A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)BMJ Open, 2013
- Partial ADAMTS13 deficiency in atypical hemolytic uremic syndromeBlood, 2013
- Recessive mutations in DGKE cause atypical hemolytic-uremic syndromeNature Genetics, 2013
- Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical PhenotypeClinical Journal of the American Society of Nephrology, 2010
- Genetics and complement in atypical HUSPediatric Nephrology, 2010
- Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center ExperiencePLOS ONE, 2010
- Glycosylphosphatidylinositol-anchored protein deficiency confers resistance to apoptosis in PNHExperimental Hematology, 2009
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006
- Antibiotic Irrigation of the BladderNew England Journal of Medicine, 1979
- Decreased Cold-Insoluble Globulin in Congenital Thrombocytopenia (Upshaw-Schulman Syndrome)New England Journal of Medicine, 1979